As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
Stocks were choppy Friday, though all three main benchmarks closed with weekly gains. All eyes are on next week's Fed meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback